
Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions
Cimerli (ranibizumab-eqrn; Sandoz) is a recombinant humanized monoclonal antibody fragment that functions as a vascular endothelial growth factor (VEGF) inhibitor. It is an interchangeable biosimilar to ranibizumab (Lucentis; Genentech), which is a …